Daunorubicin is a cytotoxic anthracycline antibiotic derived from *Streptomyces peucetius*. It is a cornerstone chemotherapeutic agent primarily used in the treatment of acute leukemias. It functions as a DNA intercalator and topoisomerase II inhibitor, leading to DNA damage and apoptosis in rapidly dividing cells. In the Indian context, it is a critical component of induction regimens for acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL), often used in combination with cytarabine (the '7+3' regimen).
Adult: **AML (Induction - '7+3' regimen):** 45-60 mg/m² body surface area (BSA) per day via IV infusion for 3 days (Days 1-3), combined with continuous infusion cytarabine for 7 days. **ALL:** 30-45 mg/m²/day on Days 1-3, often as part of multi-drug regimens. Dose is highly protocol-dependent.
Note: **Route:** Slow intravenous push or infusion over 5-15 minutes into the side port of a freely flowing IV line (0.9% Sodium Chloride or 5% Dextrose). **Preparation:** Use in a biosafety cabinet. Wear gloves, gown, and eye protection. Reconstitute 20mg vial with 4-10 mL of sterile water for injection to give a concentration of 2-5 mg/mL. Further dilute in 50-100 mL of IV fluid. **Critical:** Confirm venous patency before and during administration. Avoid extravasation. Have emergency management kit for vesicant extravasation readily available.
Daunorubicin exerts its cytotoxic effects through multiple, inter-related mechanisms: 1) **Intercalation:** It inserts (intercalates) between base pairs in the DNA helix, causing physical distortion and uncoiling of the DNA strand, which inhibits DNA and RNA synthesis. 2) **Topoisomerase II Inhibition:** It forms a stable ternary complex with DNA and topoisomerase II enzyme, preventing the religation of DNA strands after double-strand break induction. This leads to accumulation of irreversible DNA double-strand breaks. 3) **Free Radical Generation:** The quinone moiety of daunorubicin undergoes enzymatic reduction to form semiquinone radicals, which in turn generate reactive oxygen species (ROS), causing oxidative damage to cellular membranes, proteins, and DNA. 4) **Iron Chelation:** It chelates iron, forming complexes that further catalyze free radical production.
Pregnancy: **FDA Pregnancy Category D.** Daunorubicin is teratogenic and embryotoxic. Can cause fetal harm if administered to a pregnant woman. Women of childbearing potential must use effective contraception during and for at least 6 months after therapy. Not recommended during pregnancy unless the potential benefit justifies the risk to the fetus.
Driving: May cause fatigue, dizziness, or malaise. Patients should be cautioned about driving or operating machinery, especially during periods of peak fatigue or if experiencing these side effects.
| Cyclophosphamide | Increased risk of hemorrhagic cystitis and cardiotoxicity | Major |
| Trastuzumab, Other Anthracyclines | Synergistic cardiotoxicity, drastically increased risk of CHF | Major |
| CYP3A4 Inhibitors (e.g., Ketoconazole, Itraconazole, Clarithromycin) | Increased plasma levels of daunorubicin, leading to heightened toxicity | Moderate |
| CYP3A4 Inducers (e.g., Phenytoin, Rifampicin, Carbamazepine) | Decreased plasma levels of daunorubicin, potentially reducing efficacy | Moderate |
| Live Vaccines (e.g., MMR, Varicella) | Risk of disseminated vaccine-induced infection due to immunosuppression | Major |
| Cardioactive drugs (e.g., Calcium channel blockers) | Potential additive effect on cardiac function depression | Moderate |
| Hepatotoxic drugs (e.g., Paracetamol high dose, Azole antifungals) | Increased risk of liver damage | Moderate |
Same composition (Daunorubicin (20mg)), different brands: